Peptide and peptide-based inhibitors of SARS-CoV-2 entry

Abstract

To date, no effective vaccines or therapies are available against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pandemic agent of the coronavirus disease 2019 (COVID-19). Due to their safety, efficacy and specificity, peptide inhibitors hold great promise for the treatment of newly emerging viral pathogens. Based on the known structures of viral proteins and their cellular targets, antiviral peptides can be rationally designed and optimized. The resulting peptides may be highly specific for their respective targets and particular viral pathogens or exert broad antiviral activity. Here, we summarize the current status of peptides inhibiting SARS-CoV-2 entry and outline the strategies used to design peptides targeting the ACE2 receptor or the viral spike protein and its activating proteases furin, transmembrane serine protease 2 (TMPRSS2), or cathepsin L. In addition, we present approaches used against related viruses such as SARS-CoV-1 that might be implemented for inhibition of SARS-CoV-2 infection.

Cited by papers we hold 3

• ApoE4 associated with severe COVID-19 outcomes via downregulation of ACE2 and imbalanced RAS pathway · 2023
  Not checked
• Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy · 2021
  No notice
• IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro · 2021
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.